TY - JOUR
T1 - Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder
AU - Vaughan, Brigette
AU - Fegert, Joerg
AU - Kratochvil, Christopher J.
N1 - Funding Information:
Brigette S. Vaughan is and has been an investigator on studies funded by Eli Lilly, Shire, Abbott, Cephalon and Bristol Meyers Squibb. Christopher J. Kratochvil is supported by NIMH Grant 5K23MH06612701A1. He receives grant support from Eli Lilly, McNeil, Shire, Abbott, Somerset and Cephalon, and is a consultant for Eli Lilly, AstraZeneca, Abbott and Pfizer. He is Editor of the Brown University Child & Adolescent Psychopharmacology Update, member of the REACH Institute Primary Pediatric Psychopharmacology Steering Committee, member of the American Professional Society for ADHD & Related Disorders Board of Directors, and on the CME Outfitters Professional Advisory Board. He receives study drug for an NIMH-funded study from Eli Lilly. Joerg Fegert is supported by European and German national and state grants. He received industry grants and was investigator for Jansen Cilag, Eli Lilly, Medice, USB, Boehringer. He is a consultant to Jansen, Eli Lilly, Sevier and Pfizer. He is Editor-in-Chief of Child and Adolescent Psychiatry and Mental Health and European Editor of the Journal of Child and Adolescent Psychopharmacology. He is heading the commission developmental psychopharmacology of the three German professional societies in the field.
PY - 2009/3
Y1 - 2009/3
N2 - Background: Atomoxetine, an inhibitor of, the presynaptic transporter of norepinephrine, was approved for the treatment of attention-deficit/ hyperactivity disorder (ADHD) in children aged 6 years and older, adolescents and adults in the USA in 2002, and in Europe, first in the UK and then by mutual recognition in several countries during 2003 and 2004. Since that time, the use of atomoxetine has spread globally and extensive additional research has been conducted evaluating its efficacy and safety. Objective: The objective of this review is to provide a summary of the available data on atomoxetine, with an emphasis on postmarketing clinical research, which is helping to clarify the role of this agent in ADHD pharmacotherapy. Methods: Recent as well as long-term safety and efficacy data are reviewed, with an emphasis on comparison with long-acting psychostimulants, ADHD in special populations and in patients with psychiatric comorbidities. Results/conclusion: Atomoxetine is an effective acute and long-term pharmacotherapy for ADHD, and may play a particular role in the treatment of patients with comorbid disorders and those who have failed or are unable to tolerate stimulants.
AB - Background: Atomoxetine, an inhibitor of, the presynaptic transporter of norepinephrine, was approved for the treatment of attention-deficit/ hyperactivity disorder (ADHD) in children aged 6 years and older, adolescents and adults in the USA in 2002, and in Europe, first in the UK and then by mutual recognition in several countries during 2003 and 2004. Since that time, the use of atomoxetine has spread globally and extensive additional research has been conducted evaluating its efficacy and safety. Objective: The objective of this review is to provide a summary of the available data on atomoxetine, with an emphasis on postmarketing clinical research, which is helping to clarify the role of this agent in ADHD pharmacotherapy. Methods: Recent as well as long-term safety and efficacy data are reviewed, with an emphasis on comparison with long-acting psychostimulants, ADHD in special populations and in patients with psychiatric comorbidities. Results/conclusion: Atomoxetine is an effective acute and long-term pharmacotherapy for ADHD, and may play a particular role in the treatment of patients with comorbid disorders and those who have failed or are unable to tolerate stimulants.
KW - ADHD
KW - Atomoxetine
KW - Pharmacotherapy
KW - Stimulant
UR - http://www.scopus.com/inward/record.url?scp=65649121932&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=65649121932&partnerID=8YFLogxK
U2 - 10.1517/14656560902762873
DO - 10.1517/14656560902762873
M3 - Review article
C2 - 19239401
AN - SCOPUS:65649121932
SN - 1465-6566
VL - 10
SP - 669
EP - 676
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy
IS - 4
ER -